Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

240 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Feasibility of flowcytometric quantitation of immune effector cell subsets in the sentinel lymph node of the breast after cryopreservation.
van Pul KM, Vuylsteke RJ, Bril H, Stockmann HB, de Gruijl TD. van Pul KM, et al. Among authors: de gruijl td. J Immunol Methods. 2012 Jan 31;375(1-2):189-95. doi: 10.1016/j.jim.2011.10.011. Epub 2011 Oct 26. J Immunol Methods. 2012. PMID: 22062586
Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells.
Vuylsteke RJ, van Leeuwen PA, Meijer S, Wijnands PG, Statius Muller MG, Busch DH, Scheper RJ, de Gruijl TD. Vuylsteke RJ, et al. Among authors: de gruijl td. Am J Pathol. 2002 Jul;161(1):19-26. doi: 10.1016/S0002-9440(10)64152-1. Am J Pathol. 2002. PMID: 12107085 Free PMC article.
Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma.
Vuylsteke RJ, Molenkamp BG, Gietema HA, van Leeuwen PA, Wijnands PG, Vos W, van Diest PJ, Scheper RJ, Meijer S, de Gruijl TD. Vuylsteke RJ, et al. Among authors: de gruijl td. Cancer Res. 2004 Nov 15;64(22):8456-60. doi: 10.1158/0008-5472.CAN-03-3251. Cancer Res. 2004. PMID: 15548718 Clinical Trial.
Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells.
Molenkamp BG, Vuylsteke RJ, van Leeuwen PA, Meijer S, Vos W, Wijnands PG, Scheper RJ, de Gruijl TD. Molenkamp BG, et al. Among authors: de gruijl td. Am J Pathol. 2005 Nov;167(5):1301-7. doi: 10.1016/S0002-9440(10)61217-5. Am J Pathol. 2005. PMID: 16251414 Free PMC article.
Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content.
Vuylsteke RJ, Molenkamp BG, van Leeuwen PA, Meijer S, Wijnands PG, Haanen JB, Scheper RJ, de Gruijl TD. Vuylsteke RJ, et al. Among authors: de gruijl td. Clin Cancer Res. 2006 May 1;12(9):2826-33. doi: 10.1158/1078-0432.CCR-05-2431. Clin Cancer Res. 2006. PMID: 16675577 Clinical Trial.
Immunomodulation of the melanoma sentinel lymph node: a novel adjuvant therapeutic option.
Molenkamp BG, van Leeuwen PA, van den Eertwegh AJ, Sluijter BJ, Scheper RJ, Meijer S, de Gruijl TD. Molenkamp BG, et al. Among authors: de gruijl td. Immunobiology. 2006;211(6-8):651-61. doi: 10.1016/j.imbio.2006.06.009. Epub 2006 Jul 28. Immunobiology. 2006. PMID: 16920504 Review.
Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients.
Molenkamp BG, van Leeuwen PA, Meijer S, Sluijter BJ, Wijnands PG, Baars A, van den Eertwegh AJ, Scheper RJ, de Gruijl TD. Molenkamp BG, et al. Among authors: de gruijl td. Clin Cancer Res. 2007 May 15;13(10):2961-9. doi: 10.1158/1078-0432.CCR-07-0050. Clin Cancer Res. 2007. PMID: 17504997 Clinical Trial.
Inducing antitumor T cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model.
Santegoets SJ, Bontkes HJ, Stam AG, Bhoelan F, Ruizendaal JJ, van den Eertwegh AJ, Hooijberg E, Scheper RJ, de Gruijl TD. Santegoets SJ, et al. Among authors: de gruijl td. J Immunol. 2008 Apr 1;180(7):4540-9. doi: 10.4049/jimmunol.180.7.4540. J Immunol. 2008. PMID: 18354176
The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity.
Houtenbos I, Santegoets S, Westers TM, Waisfisz Q, Kipriyanov S, Denkers F, Scheper RJ, de Gruijl TD, Ossenkoppele GJ, van de Loosdrecht AA. Houtenbos I, et al. Among authors: de gruijl td. Br J Haematol. 2008 Jun;142(2):273-83. doi: 10.1111/j.1365-2141.2008.06990.x. Epub 2008 May 19. Br J Haematol. 2008. PMID: 18492117
Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, Wijnands PG, Haanen JB, van den Eertwegh AJ, Scheper RJ, de Gruijl TD. Molenkamp BG, et al. Among authors: de gruijl td. Clin Cancer Res. 2008 Jul 15;14(14):4532-42. doi: 10.1158/1078-0432.CCR-07-4711. Clin Cancer Res. 2008. PMID: 18628468 Clinical Trial.
240 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback